Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SEASTAR: A Phase 1b/2, Open-label, Parallel Arm Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor

Next Previous
Trial Profile

SEASTAR: A Phase 1b/2, Open-label, Parallel Arm Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 18 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lucitanib (Primary) ; Rucaparib (Primary) ; Sacituzumab govitecan (Primary)
  • Indications Advanced breast cancer; Carcinoma; Endometrial cancer; Ovarian cancer; Solid tumours; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SEASTAR
  • Sponsors Clovis Oncology [CEASED]; pharmaand GmbH

Most Recent Events

  • 13 Sep 2023 Number of treatment arms has been changed to 3, primary endpoint has been amended and trial focus has now shifted to Tu only.
  • 26 Jul 2022 Status changed from active, no longer recruiting to discontinued. Reason the study was stopped: Due to a change in development priorities, no further clinical development of the lucitanibplus rucaparib or lucitanib plus sacituzumab govitecan combinations is planned at this time.
  • 08 Jun 2021 Results (as of 1 Feb 2021; n= 16) presented at the 57th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top